Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-03-16 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2020年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from a shareholders' meeting (临时股东大会决议公告) held on March 16, 2020. It details the meeting attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official announcement of voting results and meeting resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2099 characters), consistent with an announcement rather than a full report.
2020-03-16 Chinese
2020年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, and voting procedures of a specific shareholders' meeting (the 2020 second extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed. The content focuses on the legal review of the shareholders' meeting process and voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short (1350 characters) and is not a full report or financial statement, but a legal opinion on the meeting and voting results, confirming the validity of the resolutions passed at the meeting. Therefore, the appropriate classification is DVA.
2020-03-16 Chinese
关于控股股东华立医药集团有限公司拟向公司提供借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related-party transaction where the controlling shareholder, Huali Pharmaceutical Group Co., Ltd., plans to provide a loan to the company and its subsidiaries. It details the loan amount, interest rate, purpose, and approval procedures including board and shareholder meeting considerations. The document is a formal disclosure of a financing-related transaction involving related parties, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive transaction details. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities and capital structure changes through related-party loans.
2020-02-27 Chinese
独立董事关于昆药集团九届二十三次董事会相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding a related-party transaction involving a loan from the controlling shareholder to the company. It discusses the fairness and compliance of the transaction but does not contain financial statements or detailed financial results. The document is short (453 characters) and serves as an announcement or opinion related to a specific board matter rather than a full report. It is not an annual report, audit report, or financial statement. It is also not a management change, earnings release, or other categories. The best fit is Regulatory Filings (RNS) as it is a regulatory announcement related to corporate governance and related-party transactions.
2020-02-27 Chinese
华立医药集团有限公司2018年合并报告
Regulatory Filings
2020-02-27 Chinese
九届十五次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. It details the approval of a borrowing plan involving the controlling shareholder and mentions the procedural steps including board and shareholder approvals. The document is short (576 characters) and serves as an official announcement of a board/committee decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a voting result announcement or a regulatory filing of another type. The content fits best under Board/Management Information (MANG) as it relates to internal governance decisions and supervisory board resolutions.
2020-02-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.